← Back to Clinical Trials
Recruiting NCT05819463

NCT05819463 Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05819463
Status Recruiting
Phase
Sponsor Swiss Society of Dermatology and Venereology
Condition Atopic Dermatitis
Study Type OBSERVATIONAL
Enrollment 700 participants
Start Date 2022-06-02
Primary Completion 2032-05

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 700 participants in total. It began in 2022-06-02 with a primary completion date of 2032-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

As structured and detailed data on the management of AD, a common chronic inflammatory skin disease which has a high impact on patients' quality of life and socioeconomic burden, are not available in Switzerland, the planned registry will overcome this gap. It will provide data on the medical care of patients with AD for health care research and allow to study the efficacy and safety of approved and available therapies for AD in daily life.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 12 years * AD according to the UK Working Party's Diagnostic Criteria (28) * Moderate to severe AD as defined by * objective SCORAD \> 20 or IGA ≥ 3 (moderate) or * currently on systemic antiinflammatory therapy for AD or * previous systemic antiinflammatory therapy for AD within past 24 months Exclusion Criteria: * refusal to sign the informed consent form

Contact & Investigator

Central Contact

Dagmar Simon, Prof. Dr. med.

✉ dagmar.simon@insel.ch

📞 +41 31 632 22 78

Principal Investigator

Dagmar Simon, Prof. Dr. med.

PRINCIPAL INVESTIGATOR

Department of Dermatology, Inselspital

Frequently Asked Questions

Who can join the NCT05819463 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05819463 currently recruiting?

Yes, NCT05819463 is actively recruiting participants. Contact the research team at dagmar.simon@insel.ch for enrollment information.

Where is the NCT05819463 trial being conducted?

This trial is being conducted at Basel, Switzerland, Bern, Switzerland, Buochs, Switzerland, Fribourg, Switzerland and 5 additional locations.

Who is sponsoring the NCT05819463 clinical trial?

NCT05819463 is sponsored by Swiss Society of Dermatology and Venereology. The principal investigator is Dagmar Simon, Prof. Dr. med. at Department of Dermatology, Inselspital. The trial plans to enroll 700 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology